A phase 1 / 2 multicenter study of BMS-986012 in subjects with relapsed/refractory small cell lung cancer.
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2014
End Date
July 31, 2022
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2014
End Date
July 31, 2022